

the Denes et al. report was given it early in her hospital stay. The available evidence supports methylprednisolone as an essential drug in the management of ADEM.

Jose Luis Soto-Hernandez*

*Instituto Nacional de Neurología Mexico, Mexico City, Mexico

References

1. Denes E, Magy L, Pradeau K, Alain S, Weinbreck P, Ranger-Roguez S. Successful treatment of human herpesvirus 6 encephalomyelitis in an immunocompetent patient. *Emerg Infect Dis*. 2004;10:729–31.
2. Mader I, Stock KW, Ettl T, Probst A. Acute disseminated encephalomyelitis: MR and CT features. *Am J Neuroradiol*. 1996;17:104–9.
3. Hartung HP, Grossman RI. ADEM: Distinct disease or part of the MS spectrum? *Neurology*. 2001;56:1257–60.
4. Tenenbaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis a long-term follow-up study of 84 pediatric patients. *Neurology*. 2002;59:1224–31.
5. Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. *Neurology*. 2001;56:1313–8.
6. Stüve O, Zamvil SS. Pathogenesis, diagnosis, and treatment of acute disseminated encephalomyelitis. *Curr Opin Neurol*. 1999;12:395–401.
7. Cohen O, Steiner-Birmanns B, Biran I, Abramsky O, Honigman O, Steiner I. Recurrence of acute disseminated encephalomyelitis at the previously affected brain site. *Arch Neurol*. 2001;58:797–801.
8. Braun DK, Dominguez G, Pellet PE. Human herpesvirus 6. *Clin Microbiol Rev*. 1997;10:521–67.
9. Caserta MT, Hall CB, Schnabel K, McIntyre K, Long C, Costanzo M, et al. Neuroinvasion and persistence of human herpesvirus 6 in children. *J Infect Dis*. 1994;170:1586–9.
10. Hall CB, Caserta MT, Schnabel KC, Long C, Epstein LG, Insel RA, et al. Persistence of human herpesvirus 6 according to site and variant: possible greater neurotropism of variant A. *Clin Infect Dis*. 1998;26:32–7.

Address for correspondence: Jose Luis Soto-Hernandez, Instituto Nacional de Neurología Mexico, Insurgentes Sur 3877, Tlalpan CP 14269, Mexico City, Mexico; fax: 525-528-7494; email: joseluis_sotohernandez@yahoo.com

In Reply: The disease that we reported (1) was encephalomyelitis induced by a human herpesvirus 6 (HHV-6) reactivation. Our aim was to emphasize that HHV-6 can cause such a disease, even when the patient is immunocompetent, and to urge physicians to search for it.

Implicating HHV-6 in the pathogenesis of neurologic manifestations in the reported case can be challenged, as suggested by Dr. Soto-Hernandez (2). Polymerase chain reaction (PCR) results must be interpreted cautiously, especially in cases that lack corroborating clinical evidence of infection. In our case, the diagnosis was made initially when HHV-6 was found in the patient's cerebral spinal fluid (CSF) by using PCR, by the absence of other cause, and by our experience; adult CSF is usually negative for HHV-6 by using PCR. Moreover, in our case, clinical symptoms and HHV-6 in the patient's CSF evolved in the same way. The neurologic tropism of HHV-6 is well known, and the main manifestation in adults is encephalitis, especially in an immunosuppressed context. Diagnosis is usually based on finding HHV-6 genetic material in the CSF (3,4), which has now replaced brain biopsy. Positive tissue results do not distinguish latent from productive infections when PCR-positive CSF indicates viral particle production in the central nervous system (CNS). In our case, the absence of brain tissue did not allow immunohistochemical staining or in situ hybridization. In the study by Caserta et al. (5), cited by Dr. Soto-Hernandez, HHV-6 PCR was positive in CSF and negative in peripheral blood mononuclear cells in 28.9% of children ≤ 3 years old with prior HHV-6 infection. These results provide evidence of HHV-6 persistence in the CNS; this phenomenon is now well recognized. Nevertheless, HHV-6 persistence after primary infection is quite different from reactivation in an immunocompetent adult. High-avidity anti-HHV-6 immuno-

globulin G detected in the patient's serum when the symptoms started proved that our patient had been infected with HHV-6 previously.

We appreciate Dr. Soto-Hernandez's suggestion concerning acute demyelinating encephalomyelitis (ADEM) in our case. ADEM is an inflammatory demyelinating disease of the CNS, occurring mostly in children and rarely in young adults, soon after an infection or a vaccination. The disease is often associated with exanthema. A virus is often thought to be the cause, but viral symptoms are often not documented and rarely treated. ADEM may evolve into multiple sclerosis, and HHV-6 has been proposed as one of the causes of that condition (6). For example, multiple sclerosis developed in 14% of children and 35% of adults with ADEM in the study by Schwarz et al. (7).

Spontaneous improvement of ADEM is regularly reported; however, when treatment is needed, especially during the acute phase, steroid therapy is frequently used. In our case, corticosteroids did not affect the evolution of the patient's neurologic symptoms. Conversely, introducing the antiherpes drugs (cidofovir and ganciclovir) was followed by improved clinical signs and negative results for HHV-6 in the CSF by PCR. Corticosteroids likely influence inflammation associated with ADEM, but if ADEM is the result of a viral infection with persistent viral replication, steroids might be deleterious, allowing an increase in viral replication (8,9).

In conclusion, we think that viruses, particularly HHV-6, should be considered in ADEM, even in immunocompetent patients. In case of a positive result, antiviral treatment must be given, eventually in association with corticosteroids. We cannot recommend using corticosteroids alone because of the risk of spreading the infection.

Eric Denes*
and Sylvie Ranger-Rogez*

*Centre Hospitalier Universitaire,
Dupuytren, Limoges, France

References

1. Denes E, Magy L, Pradeau K, Alain S, Weinbreck P, Ranger-Rogez S. Successful treatment of human herpesvirus type 6 encephalomyelitis in immunocompetent patient [letter]. *Emerg Infect Dis.* 2004;10:729–31.
2. Soto-Hernandez JL. Human herpesvirus 6 encephalomyelitis [letter]. *Emerg Infect Dis.* 2004;10:1700–1.
3. Yoshihara S, Kato R, Inoue T, Miyagawa H, Sashihara J, Kawakami M, et al. Successful treatment of life-threatening human herpesvirus-6 encephalitis with donor lymphocyte infusion in a patient who had undergone human leukocyte antigen-haploidentical nonmyeloablative stem cell transplantation. *Transplantation.* 2004;77:835–8.
4. Wainwright MS, Martin PL, Morse RP, Lacaze M, Provenzale JM, Coleman RE, et al. Human herpesvirus 6 limbic encephalitis after stem cell transplantation. *Ann Neurol.* 2001;50:612–9.
5. Caserta MT, Hall CB, Schnabel K, McIntyre K, Long C, Costanzo M, et al. Neuroinvasion and persistence of human herpesvirus 6 in children. *J Infect Dis.* 1994;170:1586–9.
6. Cermelli C, Berti R, Soldan SS, Mayne M, D'ambrosia JM, Ludwin SK, et al. High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser microdissection. *J Infect Dis.* 2003;187:1377–87.
7. Schwartz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B. Acute disseminated encephalomyelitis. A follow up study of 40 adult patients. *Neurology.* 2001;56:1313–8.
8. Hudnall SD, Rady PL, Tying SK, Fish JC. Hydrocortisone activation of human herpesvirus 8 viral DNA replication and gene expression in vitro. *Transplantation.* 1999;67:648–52.
9. Black JB, Sanderlin KC, Goldsmith CS, Gary HE, Lopez C, Pellett PE. Growth properties of human herpesvirus-6 strain Z29. *J Virol Methods.* 1989;26:133–45.

Address for correspondence: Eric Denes, Service de maladies infectieuses, Centre Hospitalier Universitaire Dupuytren, 2 Ave Martin Luther King, 87042 Limoges Cedex, France; fax: 33-5-55-05-66-48; email: eric.denes@unilim.fr

Vancomycin Heteroresistance in Methicillin- resistant *Staphylococcus aureus*, Taiwan

To the Editor: In 1997, Hiramatsu and colleagues reported the first clinical isolate of methicillin-resistant *Staphylococcus aureus* (MRSA) showing reduced susceptibility to vancomycin (1). Soon thereafter, vancomycin-intermediate *S. aureus* (VISA) or heteroresistant VISA was reported to have disseminated in Japanese hospitals (2). In Taiwan, a survey of >5,000 clinical isolates of *S. aureus* at one tertiary medical center from 1999 to 2001 showed negative results for VISA or vancomycin-resistant *S. aureus* (VRSA) (3,4). We report the first two isolations of heteroresistant VISA in Taiwan.

In June, 2000, an 89-year-old man (patient A) with a history of cerebrovascular accident underwent ileal resection for ischemic bowel disease, and primary MRSA bacteremia developed during the hospitalization. Vancomycin was given for 14 days, and his fever rapidly abated. In October 2000, a Port-A-Cath (Smiths Industries Medical Systems, Deltec, Inc., St. Paul, MN) was inserted in the left subclavian vein. On June 14, 2001, he had another blood isolate of MRSA during an episode of *Enterococcus faecalis* bacteremia. Fever resolved after 4 days of intravenous vancomycin treatment (1 g every 12 h), and vancomycin treatment was continued for 21 days. Subsequent culture of blood drawn from the Port-A-Cath and peripheral veins on June 29 and July 6, 2001, did not yield any organism. MRSA bacteremia relapsed in November 2001, and the patient received intravenous teicoplanin treatment (400 mg every 2 days) for 3 weeks, and fever resolved

rapidly. Transthoracic echocardiographic tests showed no vegetation on the cardiac valves. The patient was hospitalized again in March 2002 because of relapsing MRSA bacteremia. The Port-A-Cath was removed, and culture of fluid from the indwelling pocket yielded MRSA. Fever and MRSA bacteremia persisted, with 17 sets of positive blood culture from March to May 2002, even under an adequate dose of intravenous vancomycin (serum trough level of vancomycin = 9–24 µg/mL and serum peak level = 18–30 µg/mL) and rifampin (600 mg/day). An infected thrombus over the subclavian vein was detected by venous duplex and thought to be an unresolved focus. Linezolid (600 mg every 12 h) was given for 10 days (April 30–May 9, 2002) but discontinued because of progressive thrombocytopenia. Vancomycin and rifampin were resumed on May 10, and positive blood culture with MRSA was noted on May 14. Oliguric renal failure developed in the patient on May 21 followed by shock, and he died on May 23.

A 72-year-old man (patient B) with coronary artery disease and chronic renal insufficiency underwent coronary artery bypass grafting and aortic grafting for abdominal aortic aneurysm in December 1999. The postoperative course was complicated with second-degree atrioventricular block and progressive renal failure. He was implanted with a permanent pacemaker and started long-term hemodialysis in March 2000. In April 2000, catheter (double lumen for hemodialysis)-related MRSA bacteremia developed in the patient. Vancomycin (1 g/week) was administered and the catheter was changed, but 17 successive episodes of MRSA bacteremia recurred from May to July 2000, despite an adequate serum level of vancomycin (trough level = 13–21 µg/mL and peak level = 24–38 µg/mL). Transesophageal echocardiographic